THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF ESTROGEN RECEPTOR-LOW POSITIVE BREAST CANCER.

[1]  M. Paulli,et al.  Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature , 2023, Breast Cancer Research and Treatment.

[2]  Ali M. Al-Mashat,et al.  Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers , 2022, Breast Cancer Research and Treatment.

[3]  Keda Yu,et al.  De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort , 2022, Cancer.

[4]  T. Foukakis,et al.  The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis , 2021, ESMO open.

[5]  E. Rakha,et al.  Assessment of proliferation in breast cancer: cell cycle or mitosis? An observational study , 2021, Histopathology.

[6]  M. Barberis,et al.  Breast Cancer Heterogeneity , 2021, Diagnostics.

[7]  W. Weichert,et al.  Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Dieci,et al.  Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy , 2021, NPJ breast cancer.

[9]  Keda Yu,et al.  Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox , 2021, Cancer communications.

[10]  V. Karantza,et al.  Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea , 2021, Breast Cancer Research and Treatment.

[11]  M. Rezai,et al.  Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. , 2021, European journal of cancer.

[12]  G. Siegal,et al.  Characterization of estrogen receptor-low-positive breast cancer , 2021, Breast Cancer Research and Treatment.

[13]  O. Stoetzer,et al.  Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer , 2021, Archives of Gynecology and Obstetrics.

[14]  H. Wildiers,et al.  Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software , 2020, Histopathology.

[15]  D. Rimm,et al.  Association between low estrogen receptor positive breast cancer and staining performance , 2020, npj Breast Cancer.

[16]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Hongjian Yang,et al.  Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China , 2019, Oncology letters.

[18]  S. Bettelli,et al.  Surrogate Molecular Classification of Invasive Breast Carcinoma: A Comparison Between Core Needle Biopsy and Surgical Excision, With and Without Neoadjuvant Therapy , 2019, Applied immunohistochemistry & molecular morphology (Print).

[19]  S. Robertson,et al.  Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant , 2019, Breast Cancer Research and Treatment.

[20]  S. Noguchi,et al.  PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer , 2018, Breast Cancer Research and Treatment.

[21]  D. Dabbs,et al.  Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity , 2018, Modern Pathology.

[22]  M. Dowsett,et al.  Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients , 2018, The journal of pathology. Clinical research.

[23]  E. Fukuma,et al.  Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining , 2018, Breast Cancer.

[24]  D. Dabbs,et al.  Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? , 2018, American journal of clinical pathology.

[25]  L. Pusztai,et al.  Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Troxell,et al.  Comparison of Estrogen and Progesterone Receptor Antibody Reagents Using Proficiency Testing Data. , 2017, Archives of pathology & laboratory medicine.

[27]  Ning Zhang,et al.  Borderline ER‐Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta‐Analysis , 2017, Clinical breast cancer.

[28]  C. Blanchette,et al.  Prognostic and predictive value of low estrogen receptor expression in breast cancer. , 2017, Current oncology.

[29]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[30]  Xiao-Jun Ma,et al.  Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas. , 2016, Archives of pathology & laboratory medicine.

[31]  P. Bult,et al.  Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach , 2015, Breast Cancer Research and Treatment.

[32]  David G. Hicks,et al.  Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression , 2014, Histopathology.

[33]  A. Luini,et al.  Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. , 2014, Clinical breast cancer.

[34]  G. Hortobagyi,et al.  Which threshold for ER positivity? a retrospective study based on 9639 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Dabbs,et al.  Low ER+ breast cancer: Is this a distinct group? , 2014, American journal of clinical pathology.

[36]  N. Dendukuri,et al.  A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors , 2014, Journal of Cancer.

[37]  A. Richardson,et al.  Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. , 2013, American journal of clinical pathology.

[38]  Jianhua Wang,et al.  Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer , 2013, BMC Cancer.

[39]  I. Ellis,et al.  Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  G. Hortobagyi,et al.  Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers , 2012, Cancer.

[41]  Yuan Qi,et al.  Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[43]  M. Tiemann,et al.  Non-specific binding of antibodies in immunohistochemistry: Fakes and facts , 2011 .

[44]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[45]  Ian O Ellis,et al.  Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[47]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  I. Ellis,et al.  The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast , 2006, Journal of Clinical Pathology.

[50]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[51]  S. Pinder,et al.  E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.

[52]  K. Hasui,et al.  A new simplified catalyzed signal amplification system for minimizing non-specific staining in tissues with supersensitive immunohistochemistry. , 2005, Archives of histology and cytology.

[53]  A. Luini,et al.  Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors , 2004, Clinical Cancer Research.

[54]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[56]  P. Neven,et al.  A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[58]  Craig D. Shriver,et al.  Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype , 2012, Annals of Surgical Oncology.

[59]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.

[60]  C. Gomez-Fernandez,et al.  Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. , 2005, American journal of clinical pathology.

[61]  K. Hirakawa,et al.  Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy , 2004, Breast cancer.